Clinical Trial Update: Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer [Phase 2]

View source ↗

Summary

A phase 2 study evaluating Abraxane (nab-paclitaxel) in combination with carboplatin for recurrent platinum-sensitive ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Southeastern Gynecologic Oncology | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED